BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance

BACKGROUND: BCR-ABL1 mutation analysis is recommended for chronic myeloid leukaemia patients. However, mutations may become undetectable after changing therapy, and it is unknown whether they have been eradicated. METHODS: We examined longitudinal data of patients with imatinib-resistant mutations,...

Descripción completa

Detalles Bibliográficos
Autores principales: Parker, W T, Yeoman, A L, Jamison, B A, Yeung, D T, Scott, H S, Hughes, T P, Branford, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776970/
https://www.ncbi.nlm.nih.gov/pubmed/23799845
http://dx.doi.org/10.1038/bjc.2013.318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776970/
https://www.ncbi.nlm.nih.gov/pubmed/23799845
http://dx.doi.org/10.1038/bjc.2013.318

Ejemplares similares